

National Cancer Institute  
"Giovanni Paolo II"  
Bari Italy

NYU Cancer Institute

NYU Langone Medical Center

First Joint Meeting

# HEREDITARY BREAST & OVARIAN CANCER: RISKS AND CHALLENGES

Chairmen  
*Angelo Paradiso and Franco Muggia*

September 10-12, 2009  
National Cancer Institute - Bari, Italy

MEETING VENUE  
*Aula Magna "G. De Benedictis"  
Policlinico of Bari*



*Ministero della Salute*

 **OEI**  
Organisation of European Cancer Institutes  
European Economic Interest Grouping

**NATIONAL  
CANCER  
INSTITUTE**

Under the auspices of:



*Ministero della Salute*



**PRESIDENZA  
DELLA REGIONE PUGLIA**



Alleanza contro il cancro



**REGIONE PUGLIA**  
Assessorato alle Politiche  
del Mediterraneo



**REGIONE PUGLIA**  
Assessorato alle Politiche  
della Salute



LEGA ITALIANA PER LA LOTTA CONTRO I TUMORI  
*prevenire è vivere*



The LYNNE COHEN FOUNDATION  
FOR OVARIAN CANCER RESEARCH



Research, Education, and Early Detection



**PROVINCIA DI BARI**



**The SASS Foundation**  
for Medical Research, Inc.

**THE ADVANCED  
RESEARCH  
FOUNDATION**  
(Dr. Shubash Gulati, NYC)\*



**COMUNE DI BARI**

*In Memory of  
Dr. Ruth Simring-Friedman  
and the participants of 'Give Cancer The Boot'*

## First Biennial Meeting

The Joint Meeting “**Hereditary breast & ovarian cancer: risks and challenges**” represents a continuation of conferences independently held on this topic in the two Institution since 2003: *2<sup>nd</sup> International Workshop on Familial Breast Cancer* in the National Cancer Institute of Bari and *V Lynne Cohen Foundation Meeting* in the University of New York. The co-organizers believe that a close dialogue on scientific, ethical, and clinical issues by participants on both sides of the Atlantic may contribute to a better formulation of future questions. This meeting will be held biennially and will alternate between European and U.S. locations.

Discussion and interactions between the faculty and the participants will be strongly favoured.

## Next appointments

*New York University - USA*

**New York      March 24-26, 2011**

*National Cancer Institute “Giovanni Paolo II” - Italy*

**Bari                      September 12-14, 2013**

## Committees

### **Congress Chairs**

**Angelo Paradiso**  
Scientific Director NCI, Bari - Italy  
*a.paradiso@oncologico.bari.it*  
Tel. +39 0805555481

**Franco Muggia**  
Director of Medical Oncology Division  
New York University - USA  
*franco.muggia@nyumc.org*  
Tel. +1-2122636485

### **Local Organizing Committee**

**Angelo Paradiso**  
**Francesco Schittulli**  
**Stefania Tommasi**  
NCI - Bari, Italy - Viale Orazio Flacco, 65  
Tel +39 0805555527  
*bari.nyu09@oncologico.bari.it*

### **Scientific Secretariat**

**Cinzia Romanello Pomes**  
**Silvana Valerio**  
NCI - Bari, Italy - Viale Orazio Flacco, 65  
Tel +39 0805555434/846  
*bari.nyu09@oncologico.bari.it*

### **National Cancer Institute Management**

#### **DIRECTION**

**Nicola Pansini**  
*General Director*

**Luciano Lovecchio**  
*Administrative Director*

**Giuseppe Pastroessa**  
*Medical Office Director*

#### **CONSIGLIO DI INDIRIZZO E VERIFICA**

**Emanuele Sannicandro**  
*President*

**Michele Contino**  
**Vincenzo D'Alessandro**  
**Dorotea Dubois**  
**Annalisa Zonno**  
*Components*

# HEREDITARY BREAST & OVARIAN CANCER: RISKS AND CHALLENGES

## Thursday 10

- 15.00-15.45 Registration  
15.45-16.00 Welcome *Angelo Paradiso (I) - Franco Muggia (USA)*

## Session 1

### General aspects of prevention and diagnosis of breast and ovarian cancers

Chairs: *Angelo Paradiso (I), Franco Muggia (USA)*

- 16.00-16.20 Relevance of tumor biology to prevention and diagnosis  
*Jeff Boyd (USA)*
- 16.20-16.40 Chemoprevention: current clinical trials  
*Banu Arun (USA)*
- 16.40-17.00 Nutritional protection against breast cancer  
*Niva Shapira (IL)*
- 17.00-17.20 Innovative technology for cancer risk analysis  
*Stefania Tommasi (I)*
- 17.20-17.40 Cancer, psychological effects and medical community  
*Valerie Smaldone (USA)*

### Opening ceremony

- 18.00-18.30 *Invited authorities*
- 18.30 *Welcome cocktail*

Friday 11

Session 2

**Hereditary breast and ovarian cancers: defining the biology**

Chairs: *Stefania Tommasi (I), Helen Krontiras (USA)*

- 9.00-9.20 BRCA susceptibility genes and BC carcinogenesis  
*Daniel Silver (USA)*
- 9.20-9.40 Epigenomics and women's cancer risk  
*Martin Widschwendter (UK)*
- 9.40-9.50 Functional Characterization of the BRCA1 V1688del Sequence Alteration Recurrent in Families of Italian Ancestry: a Multimodal Approach  
*Arcangela De Nicolò (USA)*
- 9.50-10.00 Genetic and epigenetic alterations of chek2 in male breast cancer  
*Ketty Ceccarelli (I)*
- 10.00-10.15 Discussion
- 10.15-10.30 *Coffee break*

Session 3

**Hereditary breast cancers: unsolved questions**

Chairs: *Adelaide Caligo (I), Silvia Formenti (USA)*

- 10.30-10.50 Unclassified variants: guidelines for interpretation  
*Paolo Radice (I)*
- 10.50-11.10 Genetic modifiers of cancer risk  
*Antonis C Antoniou (UK)*
- 11.10-11.30 Pregnancy as a modifier of risk  
*Paolo Toniolo (USA)*
- 11.30-11.40 PALB2 mutations in italian high risk breast cancer cases  
*Irene Catucci (I), Caterina Congregati (I)*
- 11.40-11.50 SNPS' transmission in familial breast cancer  
*Brunella Pilato (I)*
- 11.50-12.15 General discussion
- 12.15-12.45 **Selected poster discussion 1**  
Biological, genetic and epigenetic aspects  
Discussants: *Stephen Reshkin (I), Gessami Sanchez-Olle (E)*
- 12.45-14.00 *Lunch*

## Session 4

### Hereditary ovarian cancer: unsolved questions

Chairs: *Chris Thomssen (D), Mack Barnes (USA)*

- 14.00-14.20 Issues in risk reducing surgery  
*Lynda Roman (USA)*
- 14.20-14.40 Cell of origin of ovarian cancer  
*Louis Dubeau (USA)*
- 14.40-14.50 Gynaecological cancer and Lynch Syndrome  
*Giuseppe Troiano (I)*
- 14.50-15.00 Discussion
- 15.00-15.15 *Coffee break*

## Session 5

### Clinical perspectives

Chairs: *Judith Balmana (E), Sudhir Srivastava (USA)*

- 15.15-15.35 Biological and clinical features of hereditary cancer  
*Angelo Paradiso (I)*
- 15.35-15.55 Mammographic density as a biomarker of risk  
*Darcy Spicer (USA)*
- 15.55-16.15 Role of magnetic resonance imaging and spectroscopy  
*Franca Podo (I)*
- 16.15-16.35 Impact of breast cancer and its detection in young women  
*Ellen Warner (CDN)*
- 16.35-16.45 Discussion
- 16.45-17.15 **Selected poster discussion 2**  
Psychological aspects  
Discussants: *Suzanne Miller (USA), Francesca Romito (I)*
- 17.15-17.45 **Selected poster discussion 3**  
Risk models and technical aspects  
Discussants: *Iman Haroun (CDN), Alessandro Monaco (I)*
- 20.30 *Social dinner*

## Saturday 12

### Session 6

#### Emerging pharmacological chance in cancer prevention

Chairs: *Francesco Schittulli (I)*, *Stephanie Blank (USA)*

- 8.50-9.10 DNA repair as a therapeutic target  
*Jos Jonkers (NKI)*
- 9.10-9.30 Clinical development of PARP-1 inhibitors  
*Hilary A Calvert (UK)*
- 9.30-9.50 BRCA effect on local control and therapeutic outcome  
*Silvia Formenti (USA)*
- 9.50-10.00 Breast cancer chemoprevention in pre-neoplastic lesions a somatostatin analog: a proof of principle trial  
*Julia Smith (USA)*
- 10.00-10.15 Discussion
- 10.15-10.30 *Coffee break*

### Session 7

#### Strategies in managing hereditary breast and ovarian cancers

Chairs: *Franca Podo (I)*, *Banu Arun (USA)*

- 10.30-10.50 Breast surgery: living up to the 'gold standard'  
*Oreste Davide Gentilini (I)*
- 10.50-11.10 Familial cancer database on-line. A web-based tool to support the clinical genetic differential diagnosis in cancer patients and families  
*Rolf H Sijmons (NKI)*
- 11.10-11.30 Ethical, legal, and social issues  
*Antonella Surbone (USA)*
- 11.30-11.40 Cancer at other sites than breast and ovary in the two branches of families with or without BRCA1/2 genes mutation  
*Rossana Lambo (I)*

### Round Table

#### Setting a hereditary cancer research agenda-panel

- 11.40-12.40 Chair: *Gordon McVie (I)*  
Panelists: *Franco Muggia (USA)*; *Angelo Paradiso (I)*; *Julia Smith (USA)*; *Sudhir Srivastava (USA)*

#### Best papers AWARDS and Conclusions

- 12.40-13.00 *Angelo Paradiso, Franco Muggia*

## Honoured Faculty

**Antoniou Antonis C**

*University of Cambridge*  
Cambridge, England

**Arun Banu**

*University of Texas, Anderson Cancer Center*  
Houston, USA

**Balmana Judith**

*Hospital Vall d'Hebron*  
Barcelona, Spain

**Barnes Mack**

*The University of Alabama  
at Birmingham*  
Birmingham, USA

**Blank Stephanie**

*New York University School of Medicine*  
New York, USA

**Boyd Jeff**

*Fox Chase Cancer Center*  
Philadelphia, USA

**Caligo Adelaide**

*University of Pisa*  
Pisa, Italy

**Catucci Irene**

*Istituto Europeo di Oncologia*  
Milano, Italy

**Calvert Hilary**

*The Medical School, Newcastle University*  
Newcastle upon Tyne, England

**Ceccarelli Ketty**

*University of Rome*  
Rome, Italy

**Congregati Caterina**

*University of Firenze*  
Firenze, Italy

**De Nicolò Arcangela**

*Dana-Farber Cancer Institute*  
Harvard Medical School  
Boston, USA

**Dubeau Louis**

*University of Southern California*  
Los Angeles, USA

**Formenti Silvia**

*Clinical Cancer Center*  
New York, USA

**Gentilini Oreste Davide**

*Istituto Europeo di Oncologia*  
Milano, Italy

**Haroun Iman**

*Odette Cancer Centre*  
Toronto, Canada

**Jonkers Jos**

*The Netherlands Cancer Institute*  
Plesmanlaan  
Amsterdam, The Netherlands

**Krontiras Helen**

*University of Alabama School of Medicine*  
Birmingham, USA

**Lambo Rossana**

*National Cancer Institute*  
"Giovanni Paolo II"  
Bari, Italy

**Mc Vie Gordon**

*Istituto Europeo di Oncologia*  
Milano, Italy

**Miller Suzanne**

*Fox Chase Cancer Center*  
Cheltenham, USA

**Monaco Alessandro**

*National Cancer Institute*  
"Giovanni Paolo II"  
Bari, Italy

**Muggia Franco**

*New York University*  
New York, USA

**Paradiso Angelo**

*National Cancer Institute*  
"Giovanni Paolo II"  
Bari, Italy

**Pilato Brunella**

*National Cancer Institute*  
"Giovanni Paolo II"  
Bari, Italy

**Podo Franca**

*Istituto Superiore di Sanità*  
Roma, Italy

**Radice Paolo**

*Istituto Nazionale Tumori*  
Milano, Italy

**Reshkin Stephen**

*University of Bari*  
Bari, Italy

**Roman Lynda**

*Womens and Childrens Hospital*  
Los Angeles, USA

**Romito Francesca**

*National Cancer Institute*  
"Giovanni Paolo II"  
Bari, Italy

**Sanchez-Olle Gessami**

*University Hospital Vall d'Hebron*  
Barcelona, Spain

**Schittulli Francesco**  
*National Cancer Institute*  
"Giovanni Paolo II"  
Bari, Italy

**Shapira Niva**  
*Clinical & Community Nutrition Tel Aviv*  
*University School for Health Professionals*  
Ramat Aviv, Israel

**Sijmons Rolf H**  
*University Medical Center Groningen (UMCG)*  
Groningen, The Netherlands

**Silver Daniel**  
*Dana-Farber Cancer Institute*  
*Harvard Medical School*  
Boston, USA

**Smaldone Valerie**  
*Guest participant*  
New York, USA

**Smith Julia**  
*New York University*  
New York, USA

**Spicer Darcy**  
*USC Norris Comprehensive Cancer Center*  
*and Hospital Los Angeles*  
Los Angeles, USA

**Srivastava Sudhir**  
*National Cancer Institute*  
Rockville, USA

**Surbone Antonella**  
*New York University*  
New York, USA

**Thomssen Christoph**  
*University Halle-Wittenberg*  
Halle (Saale), Germany

**Tommasi Stefania**  
*National Cancer Institute*  
"Giovanni Paolo II"  
Bari, Italy

**Toniolo Paolo**  
*New York University School of Medicine*  
New York, USA

**Troiano Giuseppe**  
*National Cancer Institute*  
"Giovanni Paolo II"  
Bari, Italy

**Warner Ellen**  
*Sunnybrook Health Sciences Centre*  
Toronto, Canada

**Widschwendter Martin**  
*University College London, University College*  
*London Hospital*  
London, England

### Abstracts of Selected Presentations

- |   |                     |  |
|---|---------------------|--|
| 1 | CECCARELLI KETTY    | Genetic and epigenetic alterations of chek2 in male breast cancer  |
| 2 | DE NICOLÒ ARCANGELA | Functional Characterization of the BRCA1 V1688del Sequence Alteration Recurrent in Families of Italian Ancestry: a Multimodal Approach |
| 3 | CATUCCI IRENE       | PALB2 mutations screening in Italian BRCA1 breast cancer cases   |
| 4 | CONGREGATI CATERINA | A PALB2 germline mutation associated with hereditary breast cancer in Italy  |
| 5 | PILATO BRUNELLA     | SNPS' transmission in familial breast cancer   |
| 6 | TROIANO GIUSEPPE    | Gynaecological cancer and Lynch Syndrome   |
| 7 | SMITH JULIA         | Breast cancer chemoprevention in pre-neoplastic lesions with a somatostatin analog: a proof of principle trial                         |
| 8 | LAMBO ROSSANA       | Cancer at other sites than breast and ovary in the two branches of families with or without BRCA1/2 genes mutation                     |

### Abstracts of selected poster discussion 1

#### Biological, genetic and epigenetic aspects

Discussants: *Stephen Reshkin (I), Gessami Sanchez-Olle (Spain)*

- |    |                      |   |
|----|----------------------|---|
| 9  | BALIA CRISTINA       | A homologous recombination based functional assay to classify BRCA2 variants of uncertain significance  |
| 10 | BELLIZZI ANTONIA     | The CD44+/CD24- stem cell phenotype in sporadic and familial breast cancer  |
| 11 | BORODAY NATALYA      | Biological features of hereditary breast cancer   |
| 12 | CALO' VALENTINA      | BRCA1 and BRCA2 germline mutations in Sicilian breast and/or ovarian cancer families and their association with familial profiles                                   |
| 13 | CHIARAPPA PATRIZIA   | Genomic instability in familial breast cancer patients  |
| 14 | COLOMBO MARA         | Novel BRCA1 And BRCA2 variants affecting mRNA and evaluation of the prediction efficiency of in silico tools according to nucleotide change position                |
| 15 | HONG HAO             | Role of BRCA1 in regulating the ovarian cycle   |
| 16 | MALFETTONE ANDREA    | Na <sup>+</sup> /H <sup>+</sup> exchanger regulatory factor 1 overexpression is associated with angiogenesis in familial breast cancer                              |
| 17 | OMENE CORAL          | Growth inhibition of human Triple Negative Breast Cancer (TNBC) BRCA1 model xenografts and BC stem cells by caffeic acid phenethyl ester (CAPE), a honeybee product |
| 18 | PILATO BRUNELLA      | BRCA1 large genomic rearrangements in breast and ovarian cancer families from Apulia  |
| 19 | RIZZOLO PIERA        | PIK3CA mutations in male breast cancer  |
| 20 | SANCHEZ-OLLE GESSAMI | Prevalence of BRCA1 and BRCA2 mutations in Spanish families with triple negative breast cancer (TNBC)   |
| 21 | VUTTARIELLO EMILIA   | HMGA1 protein expression in inherited breast carcinomas   |

## Abstracts of selected poster discussion 2

### Psychological aspects

Discussants: *Suzanne Miller (USA), Francesca Romito (I)*

- 22 BARILE MONICA Management of families at risk for breast and ovarian cancer. The European Institute of Oncology experience
- 23 HAROUN IMAN Determinants of a decision to undergo risk-reducing mastectomy among women with BRCA mutations on an MRI surveillance study
- 24 MILLER SUZANNE Improving at-risk women's knowledge, distress, and decision making
- 25 NOVIK YELENA Adolescent girls at risk: responses to maternal breast cancer
- 26 SASSO PATRIZIA Informative materials distributed in Italian genetic counselling services: an Italian survey
- 27 SMALDONE VALERIE The psychological effects of ovarian cancer on patients, and how the medical community can address them: a discussion led by a former ovarian cancer patient
- 28 TATONE ANNARITA The "Construct Resilience" in patients with diagnosis of breast cancer

## Abstracts of selected poster discussion 3

### Risk models and technical aspects

Discussants: *Iman Haroun (Canada), Alessandro Monaco (I)*

- 29 LAMBO ROSSANA Comparison between BRCAPRO and BOADICEA risk assessment models performance in Italian families screened for BRCA mutation
- 30 MARTAYAN ALYNE BOADICEA and BRCAPRO genetic risk models for Breast/Ovary hereditary cancer: evaluation of their mutation prediction rate on a cohort of Italian patients
- 31 ZANNA INES BRCAPRO-5 model is a useful tool in genetic counselling and clinical management of male breast cancer cases with negative family history
- 32 MONACO ALESSANDRO "Sequencing-grade" screening for BRCA-1 variants by oligo-arrays
- 33 PILATO BRUNELLA Rapid screening by Surveyor Nuclease-based mutation detection for BRCA1 and BRCA2 genes
- 34 PITOTTI ELENA I2D2 Integrated Informations DNA Database Project for the management and net sharing of diagnostic data in molecular oncology.

### Other abstracts

- 35 ARRA CLAUDIO Target therapy and cardiosafety in breast cancer: our experience
- 36 AZZARITI AMALIA In vitro characterization of AG16499, a PARP inhibitor, in breast and pancreas cancer models
- 37 BARBIERI ANTONIO Orthotopic animal model of ovarian cancer: new therapeutics approaches
- 38 GAETANI SANCIA Caco-2 cells as an intestinal in vitro model to assess intestinal bioavailability of CAPE, a propolis bioactive component with anti tumoral effects
- 39 KOZETA FILIPI Genital HR HPV circulation among young and mature women in Albania
- 40 RANIERI GIROLAMO Tryptase-positive mast cells and protease-activated receptor-2 expression paralleled with microvascular density in breast cancer patients

### **CME Credits - Continuing Medical Education Credits**

The scientific program of “Hereditary breast & ovarian cancers: risks and challenges” meeting has been submitted for the accreditation by the Italian Ministry of Health and by European Accreditation Council for Continuing Medical Education.

The present meeting obtained n. 6 Italian CME credits and n. 11 credits from the European Accreditation Council for Continuing Medical Education (EACCME), an institution of the European Union of Medical Specialists (UEMS).

Continuing education (CE) statements of credit will be available after the meeting to all attendees who have successfully completed a *Program Evaluation and Continuing Education* booklet.

Participants must be registered for “Hereditary breast & ovarian cancers: risks and challenges” Meeting in order to obtain credit.

### **AWARDS**

During the three “Poster Selected Discussion” session, an International Committee will select one poster for each session to be awarded.

### **Meeting Venue:**

Aula Magna “G. De Benedictis” Policlinico Bari  
p.zza G. Cesare 11  
Bari, Italy

### **CME Secretariat**


Patrizia Nardulli  
Annamaria Quaranta  
Marisa Longo  
Alessandra Renna  
National Cancer Institute “Giovanni Paolo II”  
Tel. +39 0805555141  
e-mail: m.longo@oncologico.bari.it

### **Organizing Secretariat**

**Intermeeting**  
Via Amendola, 172/C  
c/o Executive Center  
70126 Bari, Italy  
Tel. +39 0805482005 - +39 0805461653  
Fax +39 0805529862  
Mobile Phone 338 2995799

## Transport and Access

The Aula Magna of Policlinico - piazza Giulio Cesare 11, Bari



Aula Magna of Policlinico


**Airport:** Distance 8 km. By ring road (S.S. 16), exit 10/A Bari Picone direction "centro".

**Train station:** Distance 1 km. You can reach the site of the congress by taxi or by bus, line n. 6

**By Car:** *If you are driving from the North:* Main road 16, ring road, exit 10/A Bari Picone and follow the sign for Policlinico.  
*If you are driving from the South:* Main road 16, ring road, exit 10/A Bari Picone and follow the sign for Policlinico.

**By bus:** Lines 6 - 8 - 9 - 10 - 27 - 35

**MAP:** Aula Magna "G. De Benedictis" at Policlinico of Bari: Piazza Giulio Cesare, 11. Map, point 5.



With the support of:



**TRANSGENOMIC®**  
*the power of discovery*



**Molecular Stamping**

With the support of:

